606results about "Anaesthetics" patented technology

The invention belongs to the technical field of medical and mechanical combinations, and discloses a high-permeability and low-sensitivity ripdicaine wound patch and a preparation method thereof.The high-permeability and low-sensitivity ripdicaine wound patch comprises a wound patch body, and the wound patch body is prepared from, by mass, 0.1%-0.4% of sodium hyaluronate, 1.5%-3.5% of lidocaine, 1.5%-3.5% of prilocaine, 3%-10% of solvent, 0.5%-8% of emulsifier, 2%-10% of humectant, 0.1%-5% of soothing agent, 0.1%-1.5% of stabilizer, 0.1%-1% of thickener and the balance water. According to the present invention, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, the total amount of the raw materials is 100%, and the total amount of the raw materials is 100%. And the anesthetic has the advantages of quick effect taking, low sensitivity, capability of resisting moist heat sterilization and good stability.

The present invention relates to the technical field of pharmaceutical chemistry, and provides a heterocyclic compound and a pharmaceutical use thereof. The structure of the heterocyclic compound is as shown in formula II. The compound of the present invention has high-efficiency sedative, hypnotic and / or anesthetic effects, can control status epilepticus, and also has an analgesic effect, providing a new choice for clinical preparation of a drug having the analgesic effect, a drug having the anesthetic, sedative, and hypnotic effects and / or capable of controlling status epilepticus, and a drug having both the anesthetic, sedative, and hypnotic effects and / or capable of controlling status epilepticus and also having the analgesic effect.

The invention provides a surface anesthesia application and a preparation method thereof, and belongs to the technical field of application. The surface anesthesia application is composed of a base material and anesthetic liquid, and the anesthetic liquid is prepared from, by mass, 0.5-10% of anesthetic, 0-1% of sodium hyaluronate, 0.1-10% of penetration enhancer, 0.1-1% of thickening agent, 0.01-0.5% of pH value regulator, 0.1-1% of preservative, 0-5% of emulsifier and the balance water. The surface anesthesia application prepared by the invention takes effect quickly, has a good anesthesia effect, reduces the dosage of anesthetics, and is convenient to use and low in cost.

The invention relates to the technical field of biological pharmacy, and discloses a QS-21 saponin adjuvant as well as a preparation method and application thereof, the adjuvant is a composite liposome and comprises a liposome skeleton composed of distearoyl phosphatidylcholine and cholesterol, and QS-21 saponin, monophosphoryl lipid A and a local anesthetic are jointly entrapped in the liposome skeleton. The problem that high reactogenicity and immunogenicity of potent adjuvants are difficult to consider at the same time is solved, the immunostimulation component and the pain inhibition component are jointly entrapped in the same nano-carrier, collaborative delivery in injection local is achieved, and therefore pain and swelling caused by the adjuvants are accurately inhibited. The co-entrapment structure avoids the potential inhibition effect of the free anesthetic on the immune system, the potent body fluid and cellular immune enhancement activity of the adjuvant is completely reserved, and a new technical scheme is provided for developing vaccines with high safety and strong immune efficacy.

Disclosed in the present invention are a benzodiazepine compound, a pharmaceutical composition and the use thereof. Specifically provided is a compound represented by formula I, or a stereoisomer thereof, a deuterated compound thereof, or a pharmaceutically acceptable salt thereof. The compound provided in the present invention has one or more of the following advantageous effects: (1) the compound of the present invention exhibits good intravenous sedative and anesthetic effects; (2) the compound of the present invention exhibits low drug accumulation and a good tolerance; and (3) the compound of the present invention achieves an anesthetic effect with faster recovery.

The present invention relates to the technical field of pharmaceutical chemistry, and provides a heterocyclic compound and a use thereof. The structure of the heterocyclic compound is as shown in formula II. The compound of the present invention has efficient sedative, hypnotic and / or anesthetic effects, can control the status epilepticus, further has an analgesic effect, and provides a new option for clinically preparing a drug having an analgesic effect, a drug having anesthetic, sedative and hypnotic effects and / or capable of controlling the status epilepticus, and a drug having anesthetic, sedative and hypnotic effects and / or capable of controlling the status epilepticus and also having the analgesic effect.

The invention relates to the technical field of aquatic animal living body transportation, and discloses a sea urchin long-distance transportation synergistic method based on dry transportation and anhydrous volatile anesthesia, which comprises the following steps: placing sea urchin in a closed container, using a natural volatile substance as an anesthetic, loading and volatilizing through an adsorption material, and performing anhydrous anesthesia on the sea urchin; the anesthetized sea urchin is inversely placed on a fixing support with a mesh structure in a transportation container in the posture that the mouth face faces upwards and the thorns face downwards, and the sea urchin is prevented from rolling over in the transportation process through the self-locking effect of the thorns and meshes; a functional interlayer is arranged in the fixing support, and a temperature control material and a moisturizing material are placed in the functional interlayer at the same time to maintain the temperature and humidity of the transportation environment; after transportation, the sea urchins are placed in seawater containing the cactus extract for initial recovery and then transferred to flowing natural seawater to complete unified recovery, a whole-process collaborative protection chain of anhydrous anesthesia loss prevention, dry transportation steady state maintenance and rapid water phase restoration can be constructed, and the dry transportation survival rate and quality are remarkably improved.

The invention provides a heterocyclic compound and a pharmaceutical composition and application thereof, and belongs to the technical field of pharmaceutical chemistry. The series of heterocyclic compounds prepared by the invention have efficient sedative, hypnotic and / or anesthetic effects, can control the state of epilepsy, also have an analgesic effect, and have great significance for clinically preparing drugs with the analgesic effect and drugs with anesthetic, sedative, hypnotic and / or capable of controlling the state of epilepsy. The invention provides a new choice for the medicine which has the effects of anesthesia, sedation and hypnosis and / or can control epilepsy persistence and also has an analgesic effect.

The invention discloses a novel compound rapid surface anesthetic and a preparation method thereof, and belongs to the field of pharmaceutical preparations. According to the anesthetic, core anesthetic components of lidocaine and tetracaine are compounded with propylene glycol-laurocapram synergistic penetration enhancer, menthol auxiliary penetration enhancer, carbomer 980 gel matrix, triethanolamine pH regulator, glycerol humectant, panthenol soothing agent, purified water and the like, a surface smearing agent is prepared through a specific process, and the anesthetic can be administered in combination with an iontophoresis technology. Compared with the existing surface anesthetic for the cosmetic surgery, the surface anesthetic disclosed by the invention solves the problems of slow effect taking and poor effect, can realize rapid penetration of local skin, has short anesthesia effect taking time, long duration and good effect, has no obvious irritation to the skin, has good product stability, can effectively reduce the drug toxicity, and has a good application prospect. The device is suitable for surface anesthesia of non-surgical medical beauty items such as skin beauty, laser treatment and water-light micro-needles.

The invention belongs to the technical field of pharmaceutical preparations, and relates to a riptacaine cream as well as a preparation method and application thereof, and the preparation method of the riptacaine cream comprises the following steps: preparing carbomer gel, preparing an oil phase, preparing a water phase, primarily emulsifying, homogenizing and gelating, finely homogenizing and filling. According to the invention, polyoxyethylene (54) hydrogenated castor oil is innovatively used as an auxiliary material, triple functions of a co-melting solvent, an emulsifying agent and a stabilizing agent are realized at the same time, and any liquid grease, solvent or other surfactants do not need to be additionally added in the prescription. Through a unique'water-gel-oil 'composite structure design, oil drops are physically wrapped by a carbomer gel network and are positioned in network pores, so that the mechanical stability superior to that of a conventional emulsion is provided, and no layering is generated through high-speed centrifugal test verification. In conclusion, the invention develops the riptacaine preparation which has the advantages of few types of auxiliary materials, higher stability, quicker effect taking and capability of expanding a new dosage form and a new process.

The invention belongs to the technical field of medical polymer materials, relates to an amphiphilic block copolymer, a hydrogel material containing the amphiphilic block copolymer and a preparation method and application of the amphiphilic block copolymer, and particularly discloses a poly (2-ethyl-2-oxazoline)-polyamino acid block copolymer and a preparation method and application of a hydrogel material of the poly (2-ethyl-2-oxazoline)-polyamino acid block copolymer. The hydrogel material provided by the invention has excellent injectability, and the modulus and gelation temperature of a gel preparation can be adjusted by changing the molecular weight and concentration of the amphiphilic block copolymer, so that the hydrogel material adapts to different physiological environments, is applied to different indications, and can be applied to various diseases. Compared with other hydrogel in which the chemical structure of the polymer needs to be changed, the hydrogel is more convenient.

A container for a lyophilized rapidly infusing composition is described. The container comprises a planar lidding layer attached to a well layer comprising pockets for the therapeutic product. The lidding layer may comprise an aluminum layer, a thermoplastic polymer layer, and a labeling layer. The well layer may comprise an aluminum layer, two polyamide layers, and two thermoplastic polymer layers. A drug product assembly is also disclosed, which includes at least one therapeutic product sealed within the at least one pocket of the container.

Provided in the present application are a cyclic quaternary ammonium salt compound, and a preparation method therefor and the use thereof. Further provided are the cyclic quaternary ammonium salt compound as represented by general formula (I), or an isomer or a solvate thereof and a composition thereof and the use thereof in the preparation of anesthetic or analgesic drugs. Each substituent in the general formula (I) is the same as that defined in the description.

The invention discloses a dexmedetomidine and propofol combined reagent and a combination method, and relates to the technical field of combined use of anesthetic drugs. According to the method, firstly, dexmedetomidine is subjected to intravenous pump injection within 5-15 minutes according to the dosage of 0.5-1.0 mu g / kg, propofol is given within 2 minutes after the dexmedetomidine is subjected to general anesthesia, and the dosage of the propofol can be reduced by 10%-50% compared with that of propofol which is independently used. Through pretreatment of dexmedetomidine, the anesthetic effect of propofol can be enhanced, adverse reactions such as blood pressure drop and respiratory depression can be effectively reduced, and anesthetic safety and controllability are improved. The combined reagent comprises independent containers for respectively loading the dexmedetomidine injection and the propofol emulsion, and can be packaged by adopting a double-cavity pre-filled injector, and sequential injection is realized through a controllable opening mechanism, so that unstable emulsification and titer change caused by physical mixing of medicines are avoided.

This invention provides a novel GABA structure with better efficacy, reduced side effects, and greater safety for clinical use. A This invention relates to receptor agonists, specifically a phenol derivative, its preparation method, and its use in the central nervous system. The phenol derivative provided by this invention offers more and better drug options for inducing or maintaining anesthesia in animals or humans, promoting sedation and hypnosis, and treating and / or preventing anxiety, nausea, vomiting, migraines, seizures, epilepsy, neurodegenerative diseases, and other central nervous system-related disorders.

To provide a method that selectively targets peripheral nerves without damaging the surrounding tissue and provides sustained treatment of pains.SOLUTION: A method includes injecting a biocompatible ice slurry into one or more peripheral nerves of a subject or to its surrounding area, for a duration sufficient to inhibit the peripheral nerves. The injected biocompatible ice slurry cools the peripheral nerves, and the inhibition is reversible.SELECTED DRAWING: Figure 1

Provided are a pharmaceutical composition of a kappa opioid receptor agonist, a preparation method therefor, and use thereof. The pharmaceutical composition comprises a compound represented by formula (I), a stereoisomer thereof, a metabolite thereof, or a pharmaceutically acceptable salt thereof, and an optional osmotic pressure regulator, adjusted to pH 3.0-5.0 with hydrochloric acid. The pharmaceutical composition is good in stability, has a preparation process suitable for industrial production with a simple formula, and is compatible with a clinical administration route.

The invention relates to oral analgesic compositions for alleviation of perceived nicotine irritation through inhibition or blocking of nicotine activated receptors or ion channels in the gastrointestinal tract, including the oral cavity. The composition of the invention comprises one or more nicotine sources, one or more buffering agents,5 and at least two antagonists in an effective amount to inhibit or block nicotine agonist activation of Nicotinic Acetylcholine Receptors (nAChR) and / or Transient Receptor Potential (TRP) ion channels, the at least two antagonists being selected from the group consisting of a first antagonist comprising camphor or one or more compounds resembling camphor, a second antagonist comprising eucalyptol, and a 10 third antagonist comprising (1R,2S,5R)-N-(4-Methoxyphenyl)-5-methyl-2-(1- methylethyl)cyclohexanecarboxamide (WS-12).

In some embodiments provided herein are methods of administering an adductor canal block in a patient, wherein the methods include: (a) selecting an entry point of an injection needle in a leg of the patient; (b) inserting the injection needle into the leg of the patient at the entry point; (c) identifying a first nerve in the leg of the patient; (d) administering to the first nerve saline and a pharmaceutical composition; (e) identifying a second nerve in the leg of the patient; (f) administering to the second nerve saline and the pharmaceutical composition; wherein the first nerve and second nerve are selected from the group consisting of the nerve to vastus medialis (NVM) and the saphenous nerve, and wherein the first nerve is not the second nerve, and wherein the pharmaceutical composition comprises multivesicular liposomes.

This invention relates to the field of biopharmaceutical technology, disclosing a QS-21 saponin adjuvant, its preparation method, and its applications. The adjuvant is a composite liposome comprising a liposome backbone composed of distearate phosphatidylcholine and cholesterol, with QS-21 saponin, monophosphatidyllipid A, and a local anesthetic co-encapsulated therein. This invention solves the common problem of high reactivity and immunogenicity in potent adjuvants by co-encapsulating immunostimulatory and analgesic components on the same nanocarrier, achieving synergistic delivery at the injection site, thereby precisely inhibiting adjuvant-induced pain and swelling. This co-encapsulation structure avoids the potential inhibitory effect of free anesthetics on the immune system, fully preserving the adjuvant's potent humoral and cellular immune-enhancing activity. This invention provides a new technical solution for developing vaccines with both high safety and strong immunogenicity.

The present application provides a quaternary ammonium salt compound and its preparation method and use. The compound is represented by the general formula (I), or its isomers, pharmaceutical salts, and compositions thereof can be used to prepare anesthetic or analgesic drugs. Each substituent in the general formula (I) is as defined in the specification. [Formula 1] TIFF2024519944000085.tif31143

The present invention relates to an imidazole carboxylate compound as shown in formula I, and a preparation method therefor and a use thereof. The compound can be used for preparing an anesthetic drug, and can reduce the inhibition on corticosteroid synthesis and reduce side effects.

The present invention provides a soft tissue filler composition comprising (1) a crosslinked hyaluronic acid (HA) component comprising a crosslinked mixture of (i) a first, low molecular weight HA material having a weight average molecular weight of between 0.20 MDa and 0.99 MDa, and (ii) a second, high molecular weight HA material having a weight average molecular weight of between 1.0 MDa and 4.0 MDa, wherein the weight average molecular weight of the second, high molecular weight HA material is at least twice that of the first, low molecular weight HA material, wherein the HA materials are hyaluronic acid or one or more salts thereof, wherein the crosslinked HA component has a HA concentration of between 15.0 mg / g and 20.0 mg / g, and wherein the crosslinking is achieved by use of a crosslinking agent; and (2) an uncrosslinked HA component which is HA or a salt thereof, and which has a weight average molecular weight of at least 2.0 MDa and is present in the composition in an amount of less than 5.0% w / w.

The present invention relates to a multi-layer oral thin film comprising a first and a second matrix layer, each containing at least one polymer, and a separating layer located between the first and second matrix layers, the separating layer comprising at least one polyethylene glycol. The present invention also relates to a method for producing said thin film, and its use as a medicament.

In view of the health and addiction risks associated with opiates, anesthetic emulsions are described herein comprising eutectic mixtures of local anesthetics. In some embodiments, the anesthetic emulsions release one or more local anesthetics over a period of several days for continuous pain relief. An anesthetic emulsion, in some embodiments, comprises a dispersed phase comprising a eutectic mixture of lidocaine and benzocaine, and an aqueous or aqueous- based continuous phase comprising bupivacaine.

The present invention provides a composition comprising at least one N-acetylcysteine ​​and at least one nicotinamide riboside for use in a method for preventing and / or treating a neurological disease and / or condition. In one embodiment of the present invention, the composition maintains or improves brain function, particularly brain energy deficiency. In another embodiment of the present invention, the composition improves neurological recovery and regeneration after injury or surgery. In another embodiment of the present invention, the composition can be used in a method for preventing and / or treating a neurological disease and / or condition, and / or a method for recovery after injury or surgery.

Disclosed herein are compositions and methods for treating post-surgical pain in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a NK-1 receptor antagonist and a pain medication.

Pharmaceutical combinations of etomidate derivatives and propofol and pharmaceutical compositions thereof for use in anesthesia, sedation and / or hypnosis of animals or humans. The pharmaceutical composition of the etomidate derivative and the propofol or the pharmaceutical composition of the etomidate derivative and the propofol shows an excellent synergistic effect compared with independent administration and combined administration.

The present invention provides a heterocyclic compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the description, or a salt thereof has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.